McKesson -- How the Business Works

McKesson is the largest pharmaceutical distributor in the United States, commanding approximately 41% market share in a textbook oligopoly where three companies control over 90% of all US drug distribution. The core business is deceptively simple: buy pharmaceuticals from manufacturers, warehouse and distribute them to pharmacies and hospitals, and earn a thin spread (~3.5% gross margin) on enormous volume -- over $100 billion per quarter in revenue. On top of this distribution backbone, McKesson has layered higher-margin businesses in oncology (US Oncology Network with ~3,400 providers), prescription technology (prior authorization, patient access), and medical-surgical solutions. The company is the primary distribution partner for GLP-1 medications from Novo Nordisk and Eli Lilly, handling $14 billion per quarter in GLP-1 volume alone. FY2026 adjusted EPS guidance has been raised to $38.80-$39.20, continuing a pattern of raising guidance every quarter for three consecutive fiscal years.

The oligopoly is the moat. Three companies control over 90% of US pharmaceutical distribution, and no new entrant has emerged in decades. The barriers are structural: regulatory compliance (DEA licensing, state pharmacy board requirements), massive cold-chain warehouse networks, IT integration with tens of thousands of pharmacy and hospital systems, and decades of manufacturer relationships. McKesson is the largest at ~41% share. This is not a business where a startup can disrupt with a better app -- it requires billions in physical infrastructure, regulatory approvals in every state, and trust built over decades with manufacturers who need guaranteed next-day delivery of life-saving medications. Amazon tried to enter healthcare distribution and largely retreated from wholesale. The Big 3 structure has been stable for over 20 years.

Revenue growth is automatic -- drug spending is a secular tailwind. US pharmaceutical spending grows mid-to-high single digits annually from a combination of drug price inflation, new product launches, specialty and biosimilar adoption, and the massive GLP-1 expansion. McKesson collects a toll on every dollar that flows through the distribution system. When Ozempic or Mounjaro prices increase, McKesson distributes higher-priced inventory. When new drugs launch, they need a distributor. When GLP-1 indications expand from diabetes to obesity to cardiovascular disease, more volume flows through the same infrastructure. FY26Q3 revenue of $106.2 billion is a record, and the growth rate remains in double digits.

Higher-margin services create the profit growth engine. Distribution alone would be a decent business -- stable, growing, recession-resistant. But the real compounding comes from the higher-margin services McKesson has layered on top. The Oncology and Multispecialty segment is growing 37% YoY with operating profit guided to grow 51-55% in FY2026. Prescription Technology Solutions is growing operating profit 18% on 9% revenue growth -- pure margin expansion via AI and automation. These businesses earn meaningfully higher margins than distribution and are growing much faster. Over time, they shift the overall margin profile of the company upward while the distribution backbone continues to generate massive cash flow.

Capital allocation amplifies per-share compounding. McKesson returns significant capital through share repurchases (~$2 billion per year), reducing the diluted share count by 3-4% annually from 136.6 million to 123.7 million over the past two years. Combined with double-digit revenue growth and margin expansion from higher-value services, this drives adjusted EPS growth that far exceeds revenue growth -- the 5-year adjusted EPS CAGR is 18%, versus ~11% for adjusted operating profit. Management has raised EPS guidance every quarter for three consecutive fiscal years, demonstrating an under-promise, over-deliver culture. ROIC has improved by over 1,900 basis points since FY2020, now exceeding 30%.